Gunamani Sithanandam
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gunamani Sithanandam.
Molecular and Cellular Biology | 1996
Gunamani Sithanandam; Farida Latif; Fuh Mei Duh; Ricardo A. Bernal; Ute Smola; Hua Li; Igor Kuzmin; Viktor Wixler; L. Geil; Sadeep Shrestha; Patricia Lloyd; Scott Bader; Yoshitaka Sekido; Kenneth D. Tartof; Eugene R. Zabarovsky; Michael Dean; George Klein; Michael I. Lerman; John D. Minna; Ulf R. Rapp; Rando Allikmets
NotI linking clones, localized to the human chromosome 3p21.3 region and homozygously deleted in small cell lung cancer cell lines NCI-H740 and NCI-H1450, were used to search for a putative tumor suppressor gene(s). One of these clones, NL1G210, detected a 2.5-kb mRNA in all examined human tissues, expression being especially high in the heart and skeletal muscle. Two overlapping cDNA clones containing the entire open reading frame were isolated from a human heart cDNA library and fully characterized. Computer analysis and a search of the GenBank database to reveal high sequence identity of the product of this gene to serine-threonine kinases, especially to mitogen-activated protein kinase-activated protein kinase 2, a recently described substrate of mitogen-activated kinases. Sequence identitiy was 72% at the nucleotide level and 75% at the amino acid level, strongly suggesting that this protein is a serine-threonine kinase. Here we demonstrate that the new gene, referred to as 3pK (for chromosome 3p kinase), in fact encodes a mitogen-activated protein kinase-regulated protein serine-threonine kinase with a novel substrate specificity.
Oncogene | 2005
Gunamani Sithanandam; Laura W. Fornwald; Janet R. Fields; Lucy M. Anderson
The ErbB3 receptor and the downstream signaling kinase Akt are implicated in proliferation of lung adenocarcinoma cells. Inhibition by siRNAs to ErbB3 and Akt isoforms 1, 2 and 3 was utilized to investigate the contribution of these molecules to tumor survival, spreading and invasiveness, and the roles of specific Akt isoforms. ErbB3 siRNA stably and dose-dependently suppressed ErbB3 protein for 2 days or more, and reduced cell numbers, by both suppressing cell cycle and causing apoptosis and necrosis. It also inhibited soft agar growth, cell motility and migration, and invasiveness. Akt1, 2 and 3 siRNAs had similar suppressive effects on cell number, apoptosis/necrosis and soft agar growth. However, although Akt1 siRNA had no effect on cell migration or invasion, Akt2 siRNA effectively suppressed both activities, and Akt3 siRNA had moderate effectiveness. In A549 cells, ErbB3 is indicated as having major effects on cell division, survival, motility, migration and invasiveness. All three Akt isoforms are to varying degrees involved in these cell behaviors, with Akt2 especially implicated in migration and invasion. ErbB3 and the Akts are promising targets for therapy, and siRNAs may be useful for this purpose.
Experimental Lung Research | 2000
Gayatri Ramakrishna; Gunamani Sithanandam; Robert Y.S. Cheng; Laura W. Fornwald; George T. Smith; Bhalchandra A. Diwan; Lucy M. Anderson
Although K-ras is mutated in many human and mouse lung adenocarcinomas, the function of K-ras p21 in lung is not known. We sought evidence for the prevalent hypothesis that K-ras p21 activates raf, which in turn passes the signal through the extracellular signal regulated kinases (Erks) to stimulate cell division, and that this pathway is upregulated when K-ras is mutated. Results from both mouse lung tumors and immortalized cultured E10 and C10 lung type II cells failed to substantiate this hypothesis. Lung tumors did not have more total K-ras p21 or K-ras p21 GTP than normal lung tissue, nor were high levels of these proteins found in tumors with mutant K-ras. Activated K-ras p21-GTP levels did not correlate with proliferating cell nuclear antigen. Special features of tumors with mutant K-ras included small size of carcinomas compared with carcinomas lacking this mutation, and correlation of proliferating cell nuclear antigen with raf-1. In nontransformed type II cells in culture, both total and activated K-ras p21 increased markedly at confluence but not after serum stimulation, whereas both Erk1/2 and the protein kinase Akt were rapidly activated by the serum treatment. Reverse transcriptase-polymerase chain reaction (RT-PCR) assays of K-ras mRNA indicated an increase in confluent and especially in postconfluent cells. Together the findings indicate that normal K-ras p21 activity is associated with growth arrest of lung type II cells, and that the exact contribution of mutated K-ras p21 to tumor development remains to be discovered.
Oncogene | 1998
Gunamani Sithanandam; Gayatri Ramakrishna; Bhalchandra A. Diwan; Lucy M. Anderson
Fetal mouse lung before gestation day 17 shows unique sensitivity to causation of rapidly growing tumors by N-ethylnitrosourea (ENU). Since mouse lung tumors present a mutated K-ras oncogene, we hypothesized that this special susceptibility might reflect an unusual vulnerability of the K-ras gene. Of the lung tumors caused by ENU exposure of BALB/c mice on gestation day 14, 8/25 had a codon 12 mutation in K-ras, vs 4/25 in codon 61. Of 15 tumors after day 16 exposure, three had codon 12 and four codon 61 changes. Tumors from day 18 exposure had only codon 61 mutations (11/16), all A : T to G : C changes (CGA). By contrast, codon 12 (GGT) changes included G : C to T : A, to A : T, and to C : G. These results show significant (P<0.01) shift in the sensitivity of particular K-ras codons to ENU mutation, during fetal mouse lung maturation. In a test of a possible relationship to expression of K-ras, K-ras p21 was measured in lungs of fetal mice, and found to increase markedly on day 18 in comparison to days 14 and 16. Both alkylation of DNA and base damage due to reactive oxygen species are postulated as mechanisms for mutation by ENU, whose efficacies vary with state of fetal lung maturation and K-ras expression.
Oncogene | 1990
Gunamani Sithanandam; Walter Kolch; Duh Fm; Ulf R. Rapp
Oncogene | 1992
Gunamani Sithanandam; T. Druck; L. A. Cannizzaro; G. Leuzzi; K. Huebner; U. R. Rapp
American Journal of Respiratory Cell and Molecular Biology | 2005
Gunamani Sithanandam; George T. Smith; Janet R. Fields; Laura W. Fornwald; Lucy M. Anderson
Carcinogenesis | 2003
Gunamani Sithanandam; George T. Smith; Akira Masuda; Takashi Takahashi; Lucy M. Anderson; Laura W. Fornwald
Oncogene | 1989
Gunamani Sithanandam; Michael Dean; Brennscheidt U; Beck T; Adi F. Gazdar; John D. Minna; Brauch H; Berton Zbar; Ulf R. Rapp
Carcinogenesis | 2004
Anna E. Maciag; Gunamani Sithanandam; Lucy M. Anderson